eShowcase: eCTDXPress Aspire
Regulatory submission solution addresses the needs of smaller biotech and pharma companies
Regulatory submission solution addresses the needs of smaller biotech and pharma companies
eCTDXPress Aspire
Image Solutions, Inc. (Whippany, NJ) recently released eCTDXPress Aspire, its Web-based eSubmissions software package. The electronic regulatory submissions package is targeted toward growing biotech and small pharmaceutical companies. The software enables smaller organizations the ability to create and manage submissions in-house to ensure they are correctly implemented and validated.
eCTDXPress Aspire is fully scalable, a convenient feature for companies anticipating future growth. Other features include life cycle management capability, on-site maintenance and support from Image Solutions, and the availability of ISI consultants for regulatory operations submission help—a good way for employees to gain knowledge and experience in building eCTDs in-house. The eCTDXPress Aspire package includes eCTDXPress Compiler, which helps ensure submissions are built to agency specifications, and eCTDXPress Manager, a central eCTD repository.
Image Solutions, Inc., (973) 560-0404,
Articles in this issue
almost 19 years ago
Impact of EU Directive on Clinical Developmentalmost 19 years ago
Assessing Safety in Clinical Trialsalmost 19 years ago
eShowcase: LabPas CT 2.5almost 19 years ago
Informed Consent Considerationsalmost 19 years ago
eShowcase: GlobalView EventNetalmost 19 years ago
Subject Protection Issues Gain Broad Supportalmost 19 years ago
Data Management: R.I.P. or Brave New World?almost 19 years ago
Hurricane Katrina: What Have We Learned?almost 19 years ago
Broad Introduction to CTsalmost 19 years ago
CDISC Standards Energize EDCNewsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Related Articles
- Operational Challenges of Using Overall Survival as a Primary Endpoint
September 22nd 2025
- Strategic Participant Payments for Twenty-First Century Clinical Trials
September 19th 2025